

# c-Met [pY1230/34/35] ABfinity™ Recombinant



## Rabbit Monoclonal Antibody - Purified

Catalog no. 700139

(See product label for lot information)

**Clone/PAD:** 5H27L59  
**Isotype:** IgG  
**Gene ID:** 4233  
**Protein Acc. no.:** P08581  
**Qty:** 10 mini-blots  
**Volume:** 100 µl  
**Concentration:** 0.1 mg/mL

### Formulation

PBS + 0.09% sodium azide

### Validation

See [www.invitrogen.com/antibodies](http://www.invitrogen.com/antibodies) for protocols

Validated for use in WB

### Reactivity

This antibody is specific for pY1230/34/35 and does not recognize non-phosphorylated c-Met protein.

### Immunogen

peptide

### Immunogen sequence

RDM[pY]DKE[pY][pY]SVHN

### Sequence Identity

human, mouse, feline, rat, bovine

### Sequence Homology

N/A

### Expected Reactivity

Based on sequence identity and similarity, reactivity to human, mouse, feline, rat, bovine and is expected.

### Storage

2-8°C for up to 1mo, -20°C for long term storage. Avoid repeated freezing and thawing.

### Expiration Date

Expires one year from date of receipt when stored as instructed.

### Background

c-Met is tyrosine kinase receptor composed of a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits found in many tissues (1). It expresses a transmembrane receptor-like protein, and is involved in regulating cellular proliferation, motility, morphogenesis, and apoptosis (3, 4). c-Met encodes a high-affinity receptor for hepatocyte growth factor (HGF), which activates Tyrosine kinase when HGF is bound, autophosphorylating several tyrosine residues in its cytoplasmic domain (2, 4). Additionally, c-Met overexpression has been found in a wide variety of cancer types, particularly lung cancer (3, 4).

### References

- Bottaro DP et al (1991) Identification of the hepatocyte growth factor as the *c-met* proto-oncogene product. *Science*. 251: 802-804.
- Christensen JG et al (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. *Cancer Lett* 225: 1-26.
- Ma PC et al (2003) c-Met: structure, function, and potential for therapeutic inhibition. *Cancer Metastasis*. 22: 309-325.
- Navab R et al (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NIC-H460 non-small cell lung carcinoma cells. *Neoplasia*. 11: 1292-1300.

### Applications:


	Species	Test Material	Concentration
Western Blotting	human	A549 + pervanadate	1: 2500 to 1:5000
Immunoprecipitation			Not Tested
Immunohistochemistry			Not Tested
Immunofluorescence			Not Tested
Flow Cytometry			Not Tested
Sandwich ELISA	human	A549 + pervanadate	1:100

**For research use only. CAUTION: Not for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.



**Western Blot**

Rabbit anti-c-MET[pY1230\_pY1234\_pY1235] was used to detect phosphorylated c-Met in A549 cell lysates. Lysates were used untreated (1) or treated with 1 mM Pervanadate for 15 minutes (2).

**Explanation of symbols**

Symbol	Description	Symbol	Description
	Catalogue Number		Batch code
	Research Use Only		<i>In vitro</i> diagnostic medical device
	Use by		Temperature limitation
	Manufacturer		European Community authorised representative
	Without, does not contain		With, contains
	Protect from light		Consult accompanying documents
	Directs the user to consult instructions for use (IFU), accompanying the product.		

**For research use only. CAUTION: Not for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.